ProCE Banner Activity

Addition of Daratumumab to Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed MM

Slideset Download
Conference Coverage
Daratumumab addition to standard therapy was associated with an ORR of 100% after median follow-up of 10.8 months.

Released: June 06, 2017

Expiration: June 05, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology